April Rose, MD, PhD, FRCPC
April Rose, MD, PhD, FRCPC
Clinician Scientist, McGill University
Verifisert e-postadresse på mail.mcgill.ca
Sitert av
Sitert av
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
M Dankner, AAN Rose, S Rajkumar, PM Siegel, IR Watson
Oncogene 37 (24), 3183-3199, 2018
Osteoactivin promotes breast cancer metastasis to bone
AAN Rose, F Pepin, C Russo, JE Abou Khalil, M Hallett, PM Siegel
Molecular Cancer Research 5 (10), 1001-1014, 2007
Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast CancerGPNMB Is an Indicator of Breast Cancer Recurrence
AAN Rose, AA Grosset, Z Dong, C Russo, PA MacDonald, NR Bertos, ...
Clinical cancer research 16 (7), 2147-2156, 2010
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties
AAN Rose, MG Annis, Z Dong, F Pepin, M Hallett, M Park, PM Siegel
PloS one 5 (8), e12093, 2010
GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis
AB Dydensborg, AAN Rose, BJ Wilson, D Grote, M Paquet, V Giguere, ...
Oncogene 28 (29), 2634-2642, 2009
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer
G Maric, AAN Rose, MG Annis, PM Siegel
OncoTargets and therapy 6, 839, 2013
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer
J Bendell, M Saleh, AAN Rose, PM Siegel, L Hart, S Sirpal, S Jones, ...
Journal of Clinical Oncology 32 (32), 3619-3625, 2014
Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis
AAN Rose, C Elser, M Ennis, PJ Goodwin
Breast cancer research and treatment 141 (3), 331-339, 2013
Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases
S Tabariès, V Ouellet, BE Hsu, MG Annis, AAN Rose, L Meunier, ...
Breast cancer research 17 (1), 1-18, 2015
Emerging therapeutic targets in breast cancer bone metastasis
AAN Rose, PM Siegel
Future oncology 6 (1), 55-74, 2010
Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells
M Demers, AAN Rose, AA Grosset, K Biron-Pain, L Gaboury, PM Siegel, ...
The American journal of pathology 176 (6), 3023-3031, 2010
Breast cancer-derived factors facilitate osteolytic bone metastasis
AAN Rose, PM Siegel
Bulletin du cancer 93 (9), 931-943, 2006
GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis
G Maric, MG Annis, Z Dong, AAN Rose, S Ng, D Perkins, PA MacDonald, ...
Oncogene 34 (43), 5494-5504, 2015
Targeting GPNMB with glembatumumab vedotin: current developments and future opportunities for the treatment of cancer
AAN Rose, M Biondini, R Curiel, PM Siegel
Pharmacology & therapeutics 179, 127-141, 2017
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasDual MAPK Inhibition for Class II BRAF Mutations
M Dankner, M Lajoie, D Moldoveanu, TT Nguyen, P Savage, S Rajkumar, ...
Clinical Cancer Research 24 (24), 6483-6494, 2018
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMBTargeting GPNMB in Melanoma
AAN Rose, MG Annis, DT Frederick, M Biondini, Z Dong, L Kwong, L Chin, ...
Clinical Cancer Research 22 (24), 6088-6098, 2016
Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities
A Bemmo, C Dias, AAN Rose, C Russo, P Siegel, J Majewski
PloS one 5 (8), e11981, 2010
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ...
Journal for immunotherapy of cancer 9 (1), 2021
Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?
AAN Rose, PM Siegel
Breast Cancer Research 9 (6), 1-2, 2007
Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
AAN Rose
Drugs of today (Barcelona, Spain: 1998) 55 (4), 247-264, 2019
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20